Problem
Eye floaters represent a substantial unmet need, affecting over 50% of adults; out of which 40% with moderate to severe symptoms interfere with reading, concentration, and daily life. There is currently no FDA-approved, non-surgical treatment specifically for eye floaters, leaving patients with limited options, including observation, invasive vitrectomy, or off-label YAG laser vitreolysis.
Solution
PulseMedica is developing an automated, high-precision, image-guided laser platform designed for safe, non-invasive treatment of eye floaters. The system combines AI-powered floater identification and tracking, 3D volumetric imaging, and femtosecond laser delivery to enable precise, physician-supervised treatment in an office-based setting, with potential future applications across vitreoretinal disease.
Features include:
- AI-powered floater identification and tracking;
- High-resolution 3D multimodal imaging and volumetric capture;
- Real-time eye tracking and stabilization;
- Automated, high-precision laser targeting;
- Image-guided femtosecond laser treatment;
- Physician-supervised treatment with integrated safety systems
Traction
- Completed human floater-imaging study on 250 eyes;
- Completed preclinical laser-safety studies and obtained SPE-3000 system safety certification;
- Raised over $25 million in funding;
- Established global portfolio of 65+ patent assets, 12 U.S. patents issued/allowed.
Business model
LASIK-like: B2B medical-device system sales, annual service, and per-procedure consumables and laser fees.